Drug Profile
Epacadostat - Incyte Corporation
Alternative Names: INCB-024360; INCB-24360Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer Aduro BioTech; Bristol-Myers Squibb; Columbia University; IMV; Incyte Corporation; MedImmune; Merck AG; Merck Sharp & Dohme; National Cancer Institute (USA); Sidney Kimmel Cancer Center; Stanford University; Washington University School of Medicine
- Class Antineoplastics; Halogenated hydrocarbons; Nitroso compounds; Oxadiazoles; Small molecules; Sulfonamides
- Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Urogenital cancer
- Phase II Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Glioblastoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Sarcoma; Solid tumours
- Phase I/II Cancer; Colorectal cancer; Prostate cancer
- No development reported Rectal cancer
Most Recent Events
- 11 Aug 2023 Chinook Therapeutics has been acquired by Novartis
- 02 Jun 2023 Pharmacokinetics data from a phase I trial in Non small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 14 May 2023 Incyte Corporation completes a phase I/II ECHO 206 trial in Colorectal cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in Spain and the UK (EudraCT2016-004289-25)